Trial record 4 of 5 for:
mavrilimumab in severe COVID-19
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04447469 |
|
Recruitment Status :
Completed
First Posted : June 25, 2020
Last Update Posted : September 28, 2022
|
Sponsor:
Kiniksa Pharmaceuticals, Ltd.
Information provided by (Responsible Party):
Kiniksa Pharmaceuticals, Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | November 12, 2021 |
| Actual Study Completion Date : | January 14, 2022 |
| Certification/Extension First Submitted : | September 21, 2022 |